Hussain M, et al. PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations. ESMO Congress 2019, abstract LBA12_PR.
ATTRACT: internationaal onderzoek naar nieuwe middelen zeldzame kankers
feb 2024 | Bot en wekedelentumoren, Leukemie